EMvision Medical Devices Ltd.

As of June 30, 2026, EMvision Medical Devices Ltd. carries a market capitalization of 140.83M, placing it among publicly traded companies globally. Its enterprise value stands at 127.13M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

EMvision Medical Devices Ltd.'s next confirmed earnings release is scheduled for February 24, 2027.

As of June 30, 2026, EMvision Medical Devices Ltd. has 92.96M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, EMvision Medical Devices Ltd. maintains a current ratio of 5.53, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 21.60, indicating elevated leverage, while an interest coverage ratio of -81.17 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, EMvision Medical Devices Ltd. posted a negative return on equity (ROE) of -66.39, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -43.08, reflecting losses generated across the asset base.

Over the twelve months ended June 30, 2026, EMvision Medical Devices Ltd. recorded 31,396.00 in income tax expense. The company reported a pretax loss of -8.28M and -8.32M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, EMvision Medical Devices Ltd.'s stock has declined approximately 17.57% over the past 52 weeks. The 50-day moving average sits at 1.70, while the 200-day moving average is 1.68.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -16.51M, while operating income came in at -16.93M.

As of June 30, 2026, EMvision Medical Devices Ltd. holds 17.10M in cash and equivalents against 3.41M in total debt, resulting in a net debt position of -14.37M. Total book value stands at 15.77M, with working capital of 17.77M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -9.24, meaning EMvision Medical Devices Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.